GleamWall
中文EN

MEDS DataMeds AI, Inc.

Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2030763 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-77.5%
TTM net income YoY44.2%
TTM EPS YoY187.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-92.1%
Operating margin-548.1%
Net margin-564.8%
FCF margin—
EBITDA margin-523.7%

Returns

ROE-1,706.7%
ROA-94.8%
ROIC (approx.)-153.4%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets99.6%
Debt / equity—
Current ratio0.14x
Interest coverage-6.22x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-60.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.67M$1.78M$1.56M$1.67M$3.01M$7.79M$10.86M$12.41M
Cost of revenue$2.24M$1.60M$1.39M$9.53M$2.78M$7.29M$10.17M$11.16M
Gross profit$431,880$182,204$170,221-$7.86M$231,012$505,752$692,641$1.25M
SG&A expense$3.34M$7.06M$4.87M$4.13M$30.17M$4.86M$31.17M$4.35M
Operating income-$3.37M-$7.35M-$6.02M-$25.35M-$31.55M-$5.50M-$31.35M-$3.75M
Interest expense$2.25M$1.56M$2.07M$875,719$1.43M$1.18M$1.09M$689,186
Pretax income$10.54M-$18.36M-$7.74M-$27.85M-$34.32M-$6.67M-$32.43M-$4.33M
Net income$10.59M-$18.36M-$7.74M-$27.85M-$34.32M-$6.67M-$32.43M-$4.33M
EBITDA-$3.02M-$6.99M-$5.66M-$24.55M-$30.75M-$4.70M-$30.55M-$3.10M
EPS (basic)3.29-7.13-0.07—-23.07-5.40-0.62—
EPS (diluted)2.72-7.13-0.07—-23.07-5.40-0.62—
Weighted avg. shares (diluted)3.96M2.57M104.62M—1.49M1.24M51.92M—
Balance sheet
Cash & equivalents$476,598$2.46M$51,730$42,571$4.23M$419,942$2.52M$1.03M
Receivables$1.97M$1.17M$992,147$1.14M————
Inventory$1.44M$1.51M$1.71M$1.64M$7.49M$9.03M$9.73M$9.52M
Current assets$5.22M$5.63M$2.76M$2.82M$12.82M$13.51M$16.55M$15.17M
PP&E, net$323,305$173,879$201,514$229,376$268,911$308,642$348,373$388,180
Goodwill$15.79M$14.19M$14.19M$14.19M$16.22M$16.22M$16.22M$16.22M
Intangibles$2.99M$2.95M$2.70M$2.50M$2.24M$2.02M$1.89M$1.62M
Total assets$38.73M$32.76M$30.13M$30.46M$52.78M$54.23M$58.06M$57.33M
Current liabilities$36.55M$39.41M$32.20M$29.78M$32.74M$42.40M$46.23M$38.05M
Short-term debt$16.70M$19.21M$15.17M$10.89M$12.21M$13.18M$17.71M$11.93M
Long-term debt$1.46M$12.60M$12.60M$12.60M$12.60M$10.10M$24.12M$11.46M
Total debt$18.16M$31.81M$27.77M$23.49M$24.81M$23.28M$41.84M$23.38M
Total liabilities$38.56M$52.26M$45.19M$42.91M$46.00M$53.32M$53.58M$50.60M
Shareholders' equity-$1.70M-$19.50M-$15.06M-$12.45M$6.78M$905,255$4.48M$6.73M
Net debt$17.69M$29.35M$27.72M$23.44M$20.58M$22.86M$39.32M$22.35M
Shares outstanding4.73M2.84M119.40M2.03M89.45M63.14M61.46M51.06M
Cash flow statement
Operating cash flow-$2.90M-$2.89M-$3.41M-$6.29M-$1.14M-$2.08M-$1.35M-$2.62M
Investing cash flow$723,195-$242,132-$205,098-$255,382-$221,085-$131,926-$273,133$802,554
Financing cash flow$200,000$5.54M$3.63M$2.36M$5.17M$114,281$3.11M$2.06M
Depreciation & amortization$356,421$356,597$356,824$802,602$802,794$802,796$802,872$647,241
Stock-based compensation$2.04M$1.20M$1.36M$355,698$25.72M$935,222$27.77M—

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.